https://prescriberpoint.com/class 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/4-hydroxyphenyl-pyruvate-dioxygenase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/4-hydroxyphenyl-pyruvate-dioxygenase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/5-alpha-reductase-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/5-alpha-reductase-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/5-alpha-reductase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/5-alpha-reductase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/5-lipoxygenase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/5-lipoxygenase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/acetyl-aldehyde-dehydrogenase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/acetylcholine-release-inhibitor 2026-01-02 weekly 0.8 https://prescriberpoint.com/class/acetylcholine-release-inhibitor-%5Bepc%5D 2026-03-08 weekly 0.8 https://prescriberpoint.com/class/acetylcholine-release-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/acetylcholine-release-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/acidifying-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/actinomycin-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/actively-acquired-immunity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/activin-signaling-inhibitor 2026-01-06 weekly 0.8 https://prescriberpoint.com/class/adeno-associated-virus-vector 2026-01-19 weekly 0.8 https://prescriberpoint.com/class/adenosine-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adenosine-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adenosine-triphosphate-citrate-lyase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/adenosine-triphosphate-citrate-lyase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adenosine-triphosphate-citrate-lyase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenal-steroid-synthesis-inhibitor 2026-01-15 weekly 0.8 https://prescriberpoint.com/class/adrenal-steroid-synthesis-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenal-steroid-synthesis-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenergic-alpha-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenergic-alpha-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenergic-alpha1-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenergic-alpha2-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenergic-beta-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenergic-beta-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenergic-beta1-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenergic-beta2-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenergic-beta2-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenergic-beta3-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenocorticotropic-hormone 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/adrenocorticotropic-hormone-%5Bepc%5D 2026-02-11 weekly 0.8 https://prescriberpoint.com/class/adrenocorticotropic-hormone-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/adrenocorticotropic-hormone-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aldehyde-dehydrogenase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aldosterone-antagonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/aldosterone-antagonist-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/aldosterone-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aldosterone-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/alkaline-phosphatase-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/alkaloid 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/alkaloid-%5Bepc%5D 2026-02-22 weekly 0.8 https://prescriberpoint.com/class/alkaloid-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/alkaloids-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/alkylating-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/alkylating-drug 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/alkylating-drug-%5Bepc%5D 2026-02-05 weekly 0.8 https://prescriberpoint.com/class/alkylating-drug-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/allergens-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/allylamine-antifungal 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/alpha-1-adrenergic-agonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/alpha-1-adrenergic-agonist-%5Bepc%5D 2026-04-13 weekly 0.8 https://prescriberpoint.com/class/alpha-1-adrenergic-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/alpha-adrenergic-agonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/alpha-adrenergic-agonist-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/alpha-adrenergic-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/alpha-adrenergic-blocker 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/alpha-adrenergic-blocker-%5Bepc%5D 2026-02-27 weekly 0.8 https://prescriberpoint.com/class/alpha-adrenergic-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/alpha-glucosidase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/alpha-glucosidase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/alpha-glucosidase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/alpha-glucosidases-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/alpha-hydroxy-acid-%5Bepc%5D 2026-03-30 weekly 0.8 https://prescriberpoint.com/class/alpha-hydroxy-acid-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aluminum-complex 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/aluminum-complex-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/aluminum-complex-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/alveolar-surface-tension-reduction-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/amide-local-anesthetic 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/amide-local-anesthetic-%5Bepc%5D 2026-03-29 weekly 0.8 https://prescriberpoint.com/class/amide-local-anesthetic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/amides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/amino-acid-%5Bepc%5D 2026-05-12 weekly 0.8 https://prescriberpoint.com/class/amino-acid-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/amino-acids-aromatic-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/amino-acids-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aminoglycoside-antibacterial 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/aminoglycoside-antibacterial-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/aminoglycoside-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aminoglycosides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aminoketone 2026-01-04 weekly 0.8 https://prescriberpoint.com/class/aminosalicylate 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/aminosalicylate-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/aminosalicylate-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aminosalicylic-acids-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ampa-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/amyloid-beta-directed-antibody 2026-01-07 weekly 0.8 https://prescriberpoint.com/class/amyloid-beta-directed-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/amyloid-beta-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/analogsderivatives-chemicalingredient 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/androgen 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/androgen-%5Bepc%5D 2026-02-13 weekly 0.8 https://prescriberpoint.com/class/androgen-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/androgen-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/androgen-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/androgen-receptor-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/androgen-receptor-inhibitor-%5Bepc%5D 2026-03-08 weekly 0.8 https://prescriberpoint.com/class/androgen-receptor-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/androstanes-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/angiopoietin-like-3-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/angiopoietin-like-3-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/angiotensin-2-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/angiotensin-2-receptor-blocker 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/angiotensin-2-receptor-blocker-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/angiotensin-2-receptor-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/angiotensin-2-type-1-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/angiotensin-converting-enzyme-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/angiotensin-converting-enzyme-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/angiotensin-converting-enzyme-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/angiotensin-converting-enzyme-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anthelmintic 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/anthelmintic-%5Bepc%5D 2026-03-07 weekly 0.8 https://prescriberpoint.com/class/anthelmintic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anthelmintics-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anthracycline-topoisomerase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/anthracycline-topoisomerase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anthracyclines-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anthrax-protective-antigen-directed-antibody 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/anthrax-protective-antigen-directed-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anthrax-protective-antigen-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anti-anginal 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/anti-anginal-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/anti-anginal-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anti-coagulant-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/anti-coagulant-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anti-epileptic-agent 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/anti-epileptic-agent-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/anti-epileptic-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anti-ige 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/anti-ige-%5Bepc%5D 2026-02-13 weekly 0.8 https://prescriberpoint.com/class/anti-ige-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anti-inflammatory-agents-non-steroidal-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anti-inhibitor-coagulant-complex 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/antiarrhythmic 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/antiarrhythmic-%5Bepc%5D 2026-02-14 weekly 0.8 https://prescriberpoint.com/class/antiarrhythmic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antibodies-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antibodies-monoclonal-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antibodies-monoclonal-humanized-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antibody-surface-protein-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/anticholinergic 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/anticholinergic-%5Bepc%5D 2026-02-07 weekly 0.8 https://prescriberpoint.com/class/anticholinergic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antidiarrheal 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/antidiarrheal-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antidote 2025-12-30 weekly 0.8 https://prescriberpoint.com/class/antidote-%5Bepc%5D 2026-02-07 weekly 0.8 https://prescriberpoint.com/class/antidote-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antidote-for-acetaminophen-overdose 2025-12-30 weekly 0.8 https://prescriberpoint.com/class/antidote-for-acetaminophen-overdose-%5Bepc%5D 2026-02-07 weekly 0.8 https://prescriberpoint.com/class/antidote-for-acetaminophen-overdose-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antiemetic 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/antifibrinolytic-agent 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/antifibrinolytic-agent-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/antifibrinolytic-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antigen-neutralization-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antigens-bacterial-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antigens-dermatophagoides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antigens-fungal-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antihistamine 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/antihypoglycemic-agent 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/antihypoglycemic-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antileishmanial-%5Bepc%5D 2026-02-14 weekly 0.8 https://prescriberpoint.com/class/antileishmanial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antimalarial 2025-12-30 weekly 0.8 https://prescriberpoint.com/class/antimalarial-%5Bepc%5D 2026-02-11 weekly 0.8 https://prescriberpoint.com/class/antimalarial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antimetabolite 2026-01-10 weekly 0.8 https://prescriberpoint.com/class/antimetabolite-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/antimetabolite-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antimetabolite-immunosuppressant 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/antimetabolite-immunosuppressant-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antimycobacterial 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/antimycobacterial-%5Bepc%5D 2026-03-06 weekly 0.8 https://prescriberpoint.com/class/antimycobacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antiparasitic 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/antiparasitic-%5Bepc%5D 2026-03-05 weekly 0.8 https://prescriberpoint.com/class/antiparasitic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antiprotozoal 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/antiprotozoal-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/antiprotozoal-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antirheumatic-agent 2025-12-30 weekly 0.8 https://prescriberpoint.com/class/antirheumatic-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antisense-oligonucleotide 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/antisense-oligonucleotide-%5Bepc%5D 2026-02-28 weekly 0.8 https://prescriberpoint.com/class/antisense-oligonucleotide-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antiseptic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antithrombin-directed-rna-interaction-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/antitoxins-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/apoc-iii-directed-rna-interaction-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aromatase-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/aromatase-inhibitor-%5Bepc%5D 2026-02-11 weekly 0.8 https://prescriberpoint.com/class/aromatase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aromatase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aromatic-amino-acid 2026-01-03 weekly 0.8 https://prescriberpoint.com/class/aromatic-amino-acid-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/aromatic-amino-acid-decarboxylation-inhibitor 2026-01-03 weekly 0.8 https://prescriberpoint.com/class/aromatic-amino-acid-decarboxylation-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/aromatic-amino-acid-decarboxylation-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aromatic-amino-acid-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/arteriolar-vasodilation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/arteriolar-vasodilator 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/arteriolar-vasodilator-%5Bepc%5D 2026-02-11 weekly 0.8 https://prescriberpoint.com/class/arteriolar-vasodilator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aryl-hydrocarbon-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/aryl-hydrocarbon-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ascorbic-acid-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/asparaginase-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/asparagine-specific-enzyme-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/atypical-antipsychotic 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/atypical-antipsychotic-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/atypical-antipsychotic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/autologous-cellular-immunotherapy-%5Bepc%5D 2026-04-15 weekly 0.8 https://prescriberpoint.com/class/autologous-cellular-immunotherapy-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/autologous-cultured-cell-%5Bepc%5D 2026-04-15 weekly 0.8 https://prescriberpoint.com/class/autologous-cultured-cell-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/azole-antifungal 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/azole-antifungal-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/azole-antifungal-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/azoles-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/b-cell-maturation-antigen-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/b-lymphocyte-stimulator-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/b-lymphocyte-stimulator-specific-inhibitor-%5Bepc%5D 2026-02-26 weekly 0.8 https://prescriberpoint.com/class/b-lymphocyte-stimulator-specific-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bacterial-neurotoxin-neutralization-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/barbiturate 2026-01-08 weekly 0.8 https://prescriberpoint.com/class/barbiturate-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/barbiturate-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/barbiturates-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bcg-vaccine-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bcl-2-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/bcl-2-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bcr-abl-tyrosine-kinase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/benzodiazepine 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/benzodiazepine-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/benzodiazepine-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/benzodiazepine-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/benzodiazepines-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/benzothiazole 2026-01-08 weekly 0.8 https://prescriberpoint.com/class/benzothiazole-%5Bepc%5D 2026-04-25 weekly 0.8 https://prescriberpoint.com/class/benzothiazole-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/benzothiazoles-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/beta-adrenergic-agonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/beta-adrenergic-agonist-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/beta-adrenergic-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/beta-adrenergic-blocker 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/beta-adrenergic-blocker-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/beta-adrenergic-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/beta-lactamase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/beta-lactamase-inhibitor-%5Bepc%5D 2026-03-12 weekly 0.8 https://prescriberpoint.com/class/beta-lactamase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/beta-lactamase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/beta2-adrenergic-agonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/beta2-adrenergic-agonist-%5Bepc%5D 2026-05-05 weekly 0.8 https://prescriberpoint.com/class/beta2-adrenergic-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/beta3-adrenergic-agonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/beta3-adrenergic-agonist-%5Bepc%5D 2026-04-09 weekly 0.8 https://prescriberpoint.com/class/beta3-adrenergic-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/biguanide 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/bile-acid 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/bile-acid-binding-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bile-acid-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bile-acid-sequestrant 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/bile-acid-sequestrant-%5Bepc%5D 2026-04-28 weekly 0.8 https://prescriberpoint.com/class/bile-acid-sequestrant-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bile-acids-and-salts-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bile-salt-export-pump-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bispecific-b-cell-maturation-antigen-directed-cd3-t-cell-engager-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bispecific-cd20-directed-cd3-t-cell-engager 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/bispecific-cd20-directed-cd3-t-cell-engager-%5Bepc%5D 2026-04-08 weekly 0.8 https://prescriberpoint.com/class/bispecific-cd20-directed-cd3-t-cell-engager-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bispecific-gp100-peptide-hla-directed-cd3-t-cell-engager-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bispecific-her2-directed-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/bisphosphonate 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/blood-coagulation-factors-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/blood-viscosity-reducer-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/boron-compounds-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/breast-cancer-resistance-protein-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/brutons-tyrosine-kinase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/c-type-natriuretic-peptide-analog 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/calcineurin-inhibitor-immunosuppressant 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/calcineurin-inhibitor-immunosuppressant-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/calcineurin-inhibitor-immunosuppressant-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/calcineurin-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/calcitonin 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/calcitonin-%5Bepc%5D 2026-04-28 weekly 0.8 https://prescriberpoint.com/class/calcitonin-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/calcitonin-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/calcitonin-gene-related-peptide-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/calcitonin-gene-related-peptide-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/calcitonin-gene-related-peptide-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/calcitonin-gene-related-peptide-receptor-antagonist 2025-11-02 weekly 0.8 https://prescriberpoint.com/class/calcitonin-gene-related-peptide-receptor-antagonist-%5Bepc%5D 2026-02-11 weekly 0.8 https://prescriberpoint.com/class/calcitonin-gene-related-peptide-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/calcitonin-gene-related-peptide-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/calcium-channel-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/calcium-channel-blocker 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/calcium-channel-blocker-%5Bepc%5D 2026-03-04 weekly 0.8 https://prescriberpoint.com/class/calcium-channel-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/calcium-chelating-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/calcium-sensing-receptor-agonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/calculi-dissolution-agent-%5Bepc%5D 2026-04-18 weekly 0.8 https://prescriberpoint.com/class/calculi-dissolution-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cannabinoid-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/cannabinoid-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cannabinoids-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/carbamoyl-phosphate-synthetase-1-activator-%5Bepc%5D 2026-03-08 weekly 0.8 https://prescriberpoint.com/class/carbamoyl-phosphate-synthetase-1-activator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/carbamoyl-phosphate-synthetase-1-activators-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/carbapenems-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/carbon-radioisotopes-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/carbonic-anhydrase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/carbonic-anhydrase-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/carbonic-anhydrase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/carbonic-anhydrase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/carboxypeptidase-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/carboxypeptidases-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cardiac-glycoside 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/cardiac-glycoside-%5Bepc%5D 2026-03-29 weekly 0.8 https://prescriberpoint.com/class/cardiac-glycoside-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cardiac-glycosides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cardiac-myosin-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cardiac-myosin-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/carnitine-analog 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/carnitine-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/carnitine-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/catechol-o-methyltransferase-inhibitor-%5Bepc%5D 2026-02-21 weekly 0.8 https://prescriberpoint.com/class/catechol-o-methyltransferase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/catechol-o-methyltransferase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/catecholamine 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/catecholamine-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/catecholamine-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/catecholamine-synthesis-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/catecholamine-synthesis-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/catecholamines-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ccr5-co-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd123-interaction-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd123-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd19-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd19-directed-chimeric-antigen-receptor-%5Bepc%5D 2026-04-15 weekly 0.8 https://prescriberpoint.com/class/cd19-directed-chimeric-antigen-receptor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd19-directed-cytolytic-antibody 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/cd19-directed-cytolytic-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd19-receptor-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd19-specific-chimeric-antigen-receptor-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd20-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd20-directed-cytolytic-antibody 2025-11-02 weekly 0.8 https://prescriberpoint.com/class/cd20-directed-cytolytic-antibody-%5Bepc%5D 2026-02-21 weekly 0.8 https://prescriberpoint.com/class/cd20-directed-cytolytic-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd22-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd22-directed-immunoconjugate-%5Bepc%5D 2026-02-11 weekly 0.8 https://prescriberpoint.com/class/cd22-directed-immunoconjugate-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd25-directed-cytotoxin-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd3-directed-antibody-%5Bepc%5D 2026-04-24 weekly 0.8 https://prescriberpoint.com/class/cd3-directed-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd3-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd3-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd30-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd30-directed-immunoconjugate-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd33-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd33-directed-immunoconjugate 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/cd33-directed-immunoconjugate-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd38-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd38-directed-cytolytic-antibody 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/cd38-directed-cytolytic-antibody-%5Bepc%5D 2026-02-05 weekly 0.8 https://prescriberpoint.com/class/cd38-directed-cytolytic-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd4-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd4-directed-blocking-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd52-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd52-directed-cytolytic-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd80-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cd86-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cell-mediated-immunity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/central-alpha-2-adrenergic-agonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/central-alpha-2-adrenergic-agonist-%5Bepc%5D 2026-04-18 weekly 0.8 https://prescriberpoint.com/class/central-alpha-2-adrenergic-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/central-nervous-system-depressant 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/central-nervous-system-depression-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/central-nervous-system-stimulant 2026-01-07 weekly 0.8 https://prescriberpoint.com/class/central-nervous-system-stimulant-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/central-nervous-system-stimulant-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/central-nervous-system-stimulation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/centrally-mediated-muscle-relaxation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cephalosporin-antibacterial 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/cephalosporin-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cephalosporins-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/chelating-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/chemokine-co-receptor-5-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/chemokine-receptor-type-4-interaction-%5Bepc%5D 2026-03-06 weekly 0.8 https://prescriberpoint.com/class/chemokine-receptor-type-4-interaction-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/chemokine-receptor-type-4-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/chloride-channel-activation-potentiators-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/chloride-channel-activator-%5Bepc%5D 2026-04-17 weekly 0.8 https://prescriberpoint.com/class/chloride-channel-activator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/chloride-channel-activators-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cholecalciferol-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cholecystokinin-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cholecystokinin-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cholinergic-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cholinergic-muscarinic-agonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/cholinergic-muscarinic-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cholinergic-muscarinic-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cholinergic-muscarinic-antagonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/cholinergic-muscarinic-antagonist-%5Bepc%5D 2026-02-22 weekly 0.8 https://prescriberpoint.com/class/cholinergic-muscarinic-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cholinergic-muscarinic-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cholinergic-nicotinic-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cholinergic-receptor-agonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/cholinesterase-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/cholinesterase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cholinesterase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/chondrocytes-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/classical-complement-pathway-inhibitor-%5Bepc%5D 2026-03-13 weekly 0.8 https://prescriberpoint.com/class/classical-complement-pathway-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/classical-complement-pathway-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/claudin-182-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/claudin-182-directed-cytolytic-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/colony-stimulating-factor-1-receptor-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/colony-stimulating-factor-receptor-type-1-csf-1r-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/colony-stimulating-factors-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/competitive-opioid-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/complement-5a-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/complement-5a-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/complement-c5-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/complement-c5-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/complement-c5-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/complement-factor-d-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/complement-factor-d-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/complement-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/complement-inhibitor-%5Bepc%5D 2026-02-07 weekly 0.8 https://prescriberpoint.com/class/complement-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/complement-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/contrast-agent-for-ultrasound-imaging-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/copper-chelator 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/copper-containing-intrauterine-device-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/copper-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/corticosteroid 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/corticosteroid-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/corticosteroid-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/corticosteroid-hormone-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/corticotropin-releasing-factor-type-1-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/corticotropin-releasing-factor-type-1-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cortisol-synthesis-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/cortisol-synthesis-inhibitor-%5Bepc%5D 2026-03-15 weekly 0.8 https://prescriberpoint.com/class/cortisol-synthesis-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ctla-4-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ctla-4-directed-blocking-antibody 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/ctla-4-directed-blocking-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cxc-chemokine-receptor-4-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cxc-chemokine-receptor-4-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cyclooxygenase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/cyclooxygenase-inhibitor-%5Bepc%5D 2026-05-13 weekly 0.8 https://prescriberpoint.com/class/cyclooxygenase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cyclooxygenase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cystic-fibrosis-transmembrane-conductance-regulator-potentiator 2026-01-10 weekly 0.8 https://prescriberpoint.com/class/cystic-fibrosis-transmembrane-conductance-regulator-potentiator-%5Bepc%5D 2026-03-31 weekly 0.8 https://prescriberpoint.com/class/cystic-fibrosis-transmembrane-conductance-regulator-potentiator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cystine-disulfide-reduction-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-11a1-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-11b1-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-17a1-inhibitor 2025-12-30 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-17a1-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-1a-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-1a2-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-1a2-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-2a6-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-2b6-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-2b6-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-2c19-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-2c19-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-2c8-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-2c8-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-2c9-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-2c9-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-2d6-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-2d6-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-2e1-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-3a-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-3a-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-3a-inhibitor-%5Bepc%5D 2026-02-20 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-3a-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-3a-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-3a4-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-3a4-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-3a5-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytochrome-p450-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytolytic-agent 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/cytolytic-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytomegalovirus-dna-terminase-complex-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytomegalovirus-nucleoside-analog-dna-polymerase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/cytomegalovirus-nucleoside-analog-dna-polymerase-inhibitor-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/cytomegalovirus-nucleoside-analog-dna-polymerase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytomegalovirus-pul97-kinase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/cytomegalovirus-pul97-kinase-inhibitor-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/cytomegalovirus-pul97-kinase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytomegalovirus-pul97-kinase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytoprotective-agent 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/cytotoxin-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/cytotoxins-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dander-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decorporation-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-b-lymphocyte-activation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-blood-pressure-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-cell-membrane-integrity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-cell-wall-synthesis-repair-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-central-nervous-system-disorganized-electrical-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-cholesterol-absorption-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-coagulation-factor-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-cytokine-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-diuresis-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-dna-integrity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-dna-replication-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-embryonic-implantation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-fibrinolysis-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-gi-motility-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-gi-smooth-muscle-tone-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-glycolysis-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-gnrh-secretion-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-ige-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-immunologic-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-immunologically-active-molecule-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-leukotriene-production-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-mitosis-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-platelet-aggregation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-prostaglandin-production-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-protein-synthesis-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-renal-k-excretion-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-respiratory-secretion-viscosity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-rna-integrity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-rna-replication-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-sebaceous-gland-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-sperm-motility-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/decreased-tracheobronchial-stretch-receptor-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/deoxyribonuclease-i-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/deoxyuridine-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/depigmenting-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/depolarizing-neuromuscular-blocker 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/diagnostic-dye-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dietary-cholesterol-absorption-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/dietary-cholesterol-absorption-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dihydrofolate-reductase-inhibitor-antibacterial 2026-01-10 weekly 0.8 https://prescriberpoint.com/class/dihydrofolate-reductase-inhibitor-antibacterial-%5Bepc%5D 2026-03-01 weekly 0.8 https://prescriberpoint.com/class/dihydrofolate-reductase-inhibitor-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dihydrofolate-reductase-inhibitor-antimalarial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dihydrofolate-reductase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dihydroorotate-dehydrogenase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dihydropyridine-calcium-channel-blocker 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/dihydropyridine-calcium-channel-blocker-%5Bepc%5D 2026-02-05 weekly 0.8 https://prescriberpoint.com/class/dihydropyridine-calcium-channel-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dihydropyridines-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dipeptidase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dipeptidyl-peptidase-4-inhibitor 2026-01-08 weekly 0.8 https://prescriberpoint.com/class/dipeptidyl-peptidase-4-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/dipeptidyl-peptidase-4-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dipeptidyl-peptidase-4-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/diphtheria-toxin-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/direct-thrombin-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/direct-thrombin-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/disclosing-agent-%5Bepc%5D 2026-04-21 weekly 0.8 https://prescriberpoint.com/class/disclosing-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dna-polymerase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dna-terminase-complex-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dopa-decarboxylase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dopamine-2-receptor-antagonist 2026-01-02 weekly 0.8 https://prescriberpoint.com/class/dopamine-2-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dopamine-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dopamine-and-norepinephrine-reuptake-inhibitor 2026-01-15 weekly 0.8 https://prescriberpoint.com/class/dopamine-and-norepinephrine-reuptake-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dopamine-d2-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dopamine-uptake-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/dopaminergic-agonist 2026-01-06 weekly 0.8 https://prescriberpoint.com/class/dyes-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/echinocandin-antifungal 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/echinocandin-antifungal-%5Bepc%5D 2026-03-19 weekly 0.8 https://prescriberpoint.com/class/echinocandin-antifungal-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ectoparasiticide-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/endoglycosidase 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/endoglycosidase-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/endoglycosidase-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/endothelin-receptor-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/endothelin-receptor-antagonist-%5Bepc%5D 2026-02-13 weekly 0.8 https://prescriberpoint.com/class/endothelin-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/endothelin-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/enzyme-stabilizer 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/enzyme-stabilizer-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/enzyme-stabilizers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/epidermal-growth-factor-receptor-antagonist 2025-10-22 weekly 0.8 https://prescriberpoint.com/class/epidermal-growth-factor-receptor-antagonist-%5Bepc%5D 2026-03-21 weekly 0.8 https://prescriberpoint.com/class/epidermal-growth-factor-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/epoxide-hydrolase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ergocalciferols-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ergolines-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ergot-derivative 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/ergot-derivative-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ergotamine-derivative 2026-01-03 weekly 0.8 https://prescriberpoint.com/class/erythroid-maturation-agent-%5Bepc%5D 2026-03-15 weekly 0.8 https://prescriberpoint.com/class/erythroid-maturation-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/erythropoiesis-stimulating-agent-%5Bepc%5D 2026-03-15 weekly 0.8 https://prescriberpoint.com/class/erythropoiesis-stimulating-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/erythropoietin-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ester-local-anesthetic 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/ester-local-anesthetic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/esters-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/estradiol-congeners-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/estrogen 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/estrogen-%5Bepc%5D 2026-02-05 weekly 0.8 https://prescriberpoint.com/class/estrogen-agonist-antagonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/estrogen-agonistantagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/estrogen-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/estrogen-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/estrogen-receptor-antagonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/estrogen-receptor-antagonist-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/estrogen-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/estrogen-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/estrogens-conjugated-usp-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/expectorant 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/expectorant-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/factor-viii-activator 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/factor-xa-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/factor-xa-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/factor-xa-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/factor-xa-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/farnesoid-x-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/farnesoid-x-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/farnesyltransferase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/farnesyltransferase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/fibric-acids-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/fibroblast-growth-factor-7-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/fibroblast-growth-factor-receptor-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/fluoroquinolone-antibacterial 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/fluoroquinolone-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/fluoroquinolones-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/folate-analog-metabolic-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/folate-analog-metabolic-inhibitor-%5Bepc%5D 2026-03-08 weekly 0.8 https://prescriberpoint.com/class/folate-analog-metabolic-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/folic-acid-metabolism-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/full-opioid-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/fusion-protein-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/g-protein-linked-receptor-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gaba-a-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gaba-a-receptor-positive-modulators-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gaba-b-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gadolinium-based-contrast-agent-%5Bepc%5D 2026-03-05 weekly 0.8 https://prescriberpoint.com/class/gadolinium-based-contrast-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gamma-aminobutyric-acid-a-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gamma-aminobutyric-acid-a-receptor-positive-modulator 2025-12-30 weekly 0.8 https://prescriberpoint.com/class/gamma-aminobutyric-acid-ergic-agonist 2026-01-03 weekly 0.8 https://prescriberpoint.com/class/gamma-aminobutyric-acid-ergic-agonist-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/gamma-aminobutyric-acid-ergic-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gamma-secretase-inhibitor-%5Bepc%5D 2026-03-29 weekly 0.8 https://prescriberpoint.com/class/gamma-secretase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gamma-secretase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gastrointestinal-motility-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/gastrointestinal-motility-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/general-anesthesia-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/general-anesthetic 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/general-anesthetic-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/general-anesthetic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/genetically-modified-autologous-t-cells-%5Bepc%5D 2026-04-15 weekly 0.8 https://prescriberpoint.com/class/genetically-modified-autologous-t-cells-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/genitourinary-arterial-vasodilation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glinide-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glp-1-receptor-agonist 2026-01-08 weekly 0.8 https://prescriberpoint.com/class/glp-1-receptor-agonist-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/glp-1-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glp-2-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glucagon-like-peptide-1-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glucagon-like-peptide-1-glp-1-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glucagon-like-peptide-2-chemicalingredient 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glucagon-like-peptide-2-glp-2-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glucagon-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glucose-dependent-insulinotropic-polypeptide-receptor-agonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/glucose-dependent-insulinotropic-polypeptide-receptor-agonist-%5Bepc%5D 2026-02-07 weekly 0.8 https://prescriberpoint.com/class/glucose-dependent-insulinotropic-polypeptide-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glucosylceramidase-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glucosylceramide-synthase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/glucosylceramide-synthase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glucosylceramide-synthase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glycolipid-disialoganglioside-directed-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glycolipid-disialoganglioside-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glycopeptide-antibacterial 2026-01-03 weekly 0.8 https://prescriberpoint.com/class/glycopeptide-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glycopeptides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glycoprotein-100-peptide-human-leukocyte-antigen-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/glycoside-hydrolases-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gonadotropin-%5Bepc%5D 2026-03-12 weekly 0.8 https://prescriberpoint.com/class/gonadotropin-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gonadotropin-releasing-hormone-receptor-agonist 2025-12-30 weekly 0.8 https://prescriberpoint.com/class/gonadotropin-releasing-hormone-receptor-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/gonadotropin-releasing-hormone-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gonadotropin-releasing-hormone-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/gonadotropins-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/granulocyte-colony-stimulating-factor-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/granulocyte-macrophage-colony-stimulating-factor-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/growth-hormone-receptor-antagonist 2026-01-10 weekly 0.8 https://prescriberpoint.com/class/growth-hormone-releasing-factor-analog 2026-01-04 weekly 0.8 https://prescriberpoint.com/class/growth-hormone-secretagogue-receptor-agonist-%5Bepc%5D 2026-02-22 weekly 0.8 https://prescriberpoint.com/class/growth-hormone-secretagogue-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/growth-hormone-secretagogue-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/guanylate-cyclase-activators-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/guanylate-cyclase-c-agonist 2026-01-19 weekly 0.8 https://prescriberpoint.com/class/guanylate-cyclase-c-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/guanylate-cyclase-stimulators-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hcv-ns34a-protease-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hedgehog-pathway-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/hedgehog-pathway-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/helicobacter-pylori-diagnostic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hematologic-activity-alteration-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hematopoietic-stem-cell-mobilizer-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/hematopoietic-stem-cell-mobilizer-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hemoglobin-s-polymerization-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hemoglobin-s-polymerization-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/heparin-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hepatitis-b-virus-nucleoside-analog-reverse-transcriptase-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/hepatitis-b-virus-nucleoside-analog-reverse-transcriptase-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/hepatitis-b-virus-nucleoside-analog-reverse-transcriptase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hepatitis-c-virus-ns3-4a-protease-inhibitor-%5Bepc%5D 2026-03-25 weekly 0.8 https://prescriberpoint.com/class/hepatitis-c-virus-ns34a-protease-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hepatitis-c-virus-ns5a-inhibitor-%5Bepc%5D 2026-03-25 weekly 0.8 https://prescriberpoint.com/class/hepatitis-c-virus-ns5a-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hepatitis-c-virus-nucleotide-analog-ns5b-polymerase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/her1-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/her2-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/her2-neu-receptor-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/her2-neu-receptor-antagonist-%5Bepc%5D 2026-03-20 weekly 0.8 https://prescriberpoint.com/class/her2neu-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/her2neucerbb2-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/herpes-simplex-virus-nucleoside-analog-dna-polymerase-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/herpes-simplex-virus-nucleoside-analog-dna-polymerase-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/herpes-simplex-virus-nucleoside-analog-dna-polymerase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/herpes-zoster-virus-nucleoside-analog-dna-polymerase-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/herpes-zoster-virus-nucleoside-analog-dna-polymerase-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/herpes-zoster-virus-nucleoside-analog-dna-polymerase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/herpesvirus-nucleoside-analog-dna-polymerase-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/herpesvirus-nucleoside-analog-dna-polymerase-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/herpesvirus-nucleoside-analog-dna-polymerase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/histamine-1-receptor-antagonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/histamine-1-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/histamine-1-receptor-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/histamine-2-receptor-antagonist 2026-01-02 weekly 0.8 https://prescriberpoint.com/class/histamine-2-receptor-antagonist-%5Bepc%5D 2026-02-21 weekly 0.8 https://prescriberpoint.com/class/histamine-2-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/histamine-3-receptor-antagonist-inverse-agonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/histamine-h1-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/histamine-h2-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/histone-deacetylase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/histone-deacetylase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hiv-1-post-attachment-fusion-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hiv-integrase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hiv-protease-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hmg-coa-reductase-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/hmg-coa-reductase-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/hmg-coa-reductase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/human-blood-coagulation-factor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/human-growth-hormone-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/human-immunodeficiency-virus-1-non-nucleoside-analog-reverse-transcriptase-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/human-immunodeficiency-virus-1-non-nucleoside-analog-reverse-transcriptase-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/human-immunodeficiency-virus-1-non-nucleoside-analog-reverse-transcriptase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/human-immunodeficiency-virus-1-post-attachment-fusion-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/human-immunodeficiency-virus-integrase-strand-transfer-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/human-immunodeficiency-virus-integrase-strand-transfer-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/human-immunodeficiency-virus-nucleoside-analog-reverse-transcriptase-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/human-immunodeficiency-virus-nucleoside-analog-reverse-transcriptase-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/human-immunodeficiency-virus-nucleoside-analog-reverse-transcriptase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/human-immunoglobulin-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/human-immunoglobulin-g 2025-11-12 weekly 0.8 https://prescriberpoint.com/class/human-immunoglobulin-g-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/human-immunoglobulin-g-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/human-platelet-derived-growth-factor-%5Bepc%5D 2026-05-12 weekly 0.8 https://prescriberpoint.com/class/human-platelet-derived-growth-factor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/humanized-monoclonal-antibody-fragment-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hydrolytic-lysosomal-cholesteryl-ester-specific-enzyme-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hydrolytic-lysosomal-glucocerebroside-specific-enzyme 2026-01-02 weekly 0.8 https://prescriberpoint.com/class/hydrolytic-lysosomal-glucocerebroside-specific-enzyme-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hydrolytic-lysosomal-glycogen-specific-enzyme-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hydrolytic-lysosomal-glycosaminoglycan-specific-enzyme 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/hydrolytic-lysosomal-glycosaminoglycan-specific-enzyme-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hydrolytic-lysosomal-neutral-glycosphingolipid-specific-enzyme-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hydrolytic-lysosomal-triacylglycerol-specific-enzyme-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hydroxy-acids-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hydroxymethylglutaryl-coa-reductase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hydroxyphenylpyruvate-dioxygenase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hyperpolarized-contrast-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hypoxia-inducible-factor-2-alpha-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hypoxia-inducible-factor-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hypoxia-inducible-factor-prolyl-hydroxylase-inhibitor-%5Bepc%5D 2026-04-17 weekly 0.8 https://prescriberpoint.com/class/hypoxia-inducible-factor-prolyl-hydroxylase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ige-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ileal-bile-acid-transporter-inhibitor 2026-01-02 weekly 0.8 https://prescriberpoint.com/class/ileal-bile-acid-transporter-inhibitor-%5Bepc%5D 2026-02-19 weekly 0.8 https://prescriberpoint.com/class/ileal-bile-acid-transporter-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ileal-bile-acid-transporter-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/immunoconjugates-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/immunoglobulin-g-%5Bepc%5D 2026-02-16 weekly 0.8 https://prescriberpoint.com/class/immunoglobulin-g-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/immunoglobulins-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-blood-pressure-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-cellular-death-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-coagulation-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-cytokine-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-cytokine-production-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-diuresis-at-loop-of-henle-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-diuresis-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-epithelial-proliferation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-erythroid-cell-production-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-gluconeogenesis-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-glutathione-concentration-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-glycogenolysis-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-hematopoietic-stem-cell-mobilization-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-histamine-release-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-igg-production-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-immunologically-active-molecule-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-intravascular-volume-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-lymphocyte-activation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-lymphocyte-cell-production-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-macrophage-proliferation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-megakaryocyte-maturation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-myeloid-cell-production-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-platelet-production-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-prostaglandin-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-protein-breakdown-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-protein-synthesis-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-prothrombin-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-respiratory-secretions-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-rna-degradation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-sympathetic-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-t-lymphocyte-activation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-t-lymphocyte-destruction-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/increased-uterine-smooth-muscle-contraction-or-tone-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/influenza-a-m2-protein-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/influenza-a-m2-protein-inhibitor-%5Bepc%5D 2026-02-21 weekly 0.8 https://prescriberpoint.com/class/influenza-a-m2-protein-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/inhalation-diagnostic-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/inhibit-ovum-fertilization-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/inhibition-gastric-acid-secretion-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/insect-proteins-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/insulin-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/insulin-analog 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/insulin-analog-%5Bepc%5D 2026-03-23 weekly 0.8 https://prescriberpoint.com/class/insulin-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/insulin-chemicalingredient 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/insulin-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/insulin-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/insulin-like-growth-factor-1-receptor-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/insulin-like-growth-factor-1-receptor-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/integrin-receptor-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/integrin-receptor-antagonist-%5Bepc%5D 2026-02-22 weekly 0.8 https://prescriberpoint.com/class/integrin-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/integrin-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interferon-alfa-2b 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/interferon-alfa-2b-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interferon-alfa-2b-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interferon-alpha-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interferon-alpha-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interferon-beta 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/interferon-beta-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interferon-beta-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interferon-gamma-%5Bepc%5D 2026-03-25 weekly 0.8 https://prescriberpoint.com/class/interferon-gamma-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interferon-gamma-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interferon-gamma-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interferon-gamma-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interferon-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-1-receptor-antagonist-%5Bepc%5D 2026-04-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-1-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-1-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-12-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/interleukin-12-antagonist-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/interleukin-12-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-12-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-13-antagonist 2026-01-04 weekly 0.8 https://prescriberpoint.com/class/interleukin-13-antagonist-%5Bepc%5D 2026-03-21 weekly 0.8 https://prescriberpoint.com/class/interleukin-13-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-13-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-17-receptor-a-antagonist-%5Bepc%5D 2026-02-16 weekly 0.8 https://prescriberpoint.com/class/interleukin-17-receptor-a-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-17-receptor-a-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-17a-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/interleukin-17a-antagonist-%5Bepc%5D 2026-03-21 weekly 0.8 https://prescriberpoint.com/class/interleukin-17a-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-17a-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-2-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-2-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-2-receptor-blocking-antibody 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/interleukin-2-receptor-blocking-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-2-receptor-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-23-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/interleukin-23-antagonist-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/interleukin-23-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-23-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-31-receptor-alpha-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/interleukin-31-receptor-alpha-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-31-receptor-alpha-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-36-receptor-antagonist-%5Bepc%5D 2026-03-22 weekly 0.8 https://prescriberpoint.com/class/interleukin-36-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-36-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-4-receptor-alpha-antagonist 2025-11-06 weekly 0.8 https://prescriberpoint.com/class/interleukin-4-receptor-alpha-antagonist-%5Bepc%5D 2026-03-08 weekly 0.8 https://prescriberpoint.com/class/interleukin-4-receptor-alpha-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-4-receptor-alpha-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-5-antagonist 2025-11-02 weekly 0.8 https://prescriberpoint.com/class/interleukin-5-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-5-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-5-receptor-alpha-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-5-receptor-alpha-directed-cytolytic-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-6-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-6-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-6-receptor-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/interleukin-6-receptor-antagonist-%5Bepc%5D 2026-03-14 weekly 0.8 https://prescriberpoint.com/class/interleukin-6-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/interleukin-6-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/intestinal-lipase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/iodine-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ion-exchange-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/iron-chelating-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/iron-chelator 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/iron-chelator-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/iron-chelator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/iron-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/irrigation-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/isocitrate-dehydrogenase-1-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/isocitrate-dehydrogenase-1-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/isocitrate-dehydrogenase-1-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/isocitrate-dehydrogenase-2-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/isocitrate-dehydrogenase-2-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/janus-kinase-inhibitor-%5Bepc%5D 2026-04-25 weekly 0.8 https://prescriberpoint.com/class/janus-kinase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/janus-kinase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/kallikrein-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/kinase-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/kinase-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/kinase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/kinase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/l-thyroxine 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/l-triiodothyronine 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/lead-chelating-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lead-chelator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/leptin-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/leptin-chemicalingredient 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/leukocyte-growth-factor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/leukocyte-growth-factor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/leukocytes-mononuclear-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/leukotriene-receptor-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/leukotriene-receptor-antagonist-%5Bepc%5D 2026-03-20 weekly 0.8 https://prescriberpoint.com/class/leukotriene-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/leukotriene-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lincosamide-antibacterial 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/lincosamide-antibacterial-%5Bepc%5D 2026-04-28 weekly 0.8 https://prescriberpoint.com/class/lincosamide-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lincosamides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lipase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lipid-based-polyene-antifungal-%5Bepc%5D 2026-04-23 weekly 0.8 https://prescriberpoint.com/class/lipid-based-polyene-antifungal-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lipid-emulsion 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/lipid-emulsion-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lipids-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lipoglycopeptide-antibacterial 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/lipoglycopeptide-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lipoglycopeptides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lipopeptide-antibacterial 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/lipopeptide-antibacterial-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/lipopeptide-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lipopeptides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/live-attenuated-bacillus-calmette-guerin-immunotherapy-%5Bepc%5D 2026-04-10 weekly 0.8 https://prescriberpoint.com/class/live-attenuated-bacillus-calmette-guerin-immunotherapy-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/live-attenuated-bacillus-calmette-guerin-vaccine-%5Bepc%5D 2026-04-10 weekly 0.8 https://prescriberpoint.com/class/live-attenuated-bacillus-calmette-guerin-vaccine-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/local-anesthesia-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/loop-diuretic 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/loop-diuretic-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/loop-diuretic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/low-molecular-weight-heparin 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/lymphocyte-activation-gene-3-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lymphocyte-activation-gene-3-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lymphocyte-function-alteration-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lymphocyte-function-associated-antigen-1-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lymphocyte-function-associated-antigen-1-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lymphocyte-growth-factor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/lysosomal-beta-glucuronidase 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/lysosomal-beta-glucuronidase-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/m2-protein-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/macrolide 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/macrolide-%5Bepc%5D 2026-03-12 weekly 0.8 https://prescriberpoint.com/class/macrolide-antibacterial-%5Bepc%5D 2026-02-06 weekly 0.8 https://prescriberpoint.com/class/macrolide-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/macrolide-antimicrobial 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/macrolide-antimicrobial-%5Bepc%5D 2026-03-12 weekly 0.8 https://prescriberpoint.com/class/macrolide-antimicrobial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/macrolide-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/macrolides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/magnetic-resonance-contrast-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/mast-cell-stabilizer 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/medium-chain-triglyceride 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/medium-chain-triglyceride-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/melanin-synthesis-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/melanin-synthesis-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/melanocortin-4-receptor-agonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/melanocortin-4-receptor-agonist-%5Bepc%5D 2026-04-03 weekly 0.8 https://prescriberpoint.com/class/melanocortin-4-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/melanocortin-4-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/melatonin-receptor-agonist-%5Bepc%5D 2026-03-12 weekly 0.8 https://prescriberpoint.com/class/melatonin-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/melatonin-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/menin-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/menin-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/methylating-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/methylating-agent-%5Bepc%5D 2026-04-28 weekly 0.8 https://prescriberpoint.com/class/methylating-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/methylxanthine 2026-01-08 weekly 0.8 https://prescriberpoint.com/class/methylxanthine-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/methylxanthine-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/microsomal-triglyceride-transfer-protein-inhibitor 2025-10-22 weekly 0.8 https://prescriberpoint.com/class/microtubule-inhibition-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/microtubule-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/microtubule-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/microtubule-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/mineralocorticoid-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/mitogen-activated-protein-kinase-kinase-1-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/mitogen-activated-protein-kinase-kinase-2-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/monoamine-oxidase-b-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/monoamine-oxidase-inhibitor 2026-01-08 weekly 0.8 https://prescriberpoint.com/class/monoamine-oxidase-inhibitor-%5Bepc%5D 2026-05-09 weekly 0.8 https://prescriberpoint.com/class/monoamine-oxidase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/monoamine-oxidase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/monoamine-oxidase-type-b-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/monobactam-antibacterial 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/monobactam-antibacterial-%5Bepc%5D 2026-04-18 weekly 0.8 https://prescriberpoint.com/class/monobactam-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/monobactams-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/monoclonal-antibody-%5Bepc%5D 2026-03-06 weekly 0.8 https://prescriberpoint.com/class/monoclonal-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/mood-stabilizer 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/mood-stabilizer-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/mood-stabilizer-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/mtor-inhibitor-immunosuppressant 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/mtor-inhibitor-immunosuppressant-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/mtor-inhibitor-immunosuppressant-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/mtor-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/mu-opioid-receptor-agonist-%5Bepc%5D 2026-04-21 weekly 0.8 https://prescriberpoint.com/class/mu-opioid-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/mucocutaneous-epithelial-cell-growth-factor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/mucocutaneous-epithelial-cell-growth-factor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/mucolytic 2025-12-30 weekly 0.8 https://prescriberpoint.com/class/mucolytic-%5Bepc%5D 2026-02-07 weekly 0.8 https://prescriberpoint.com/class/mucolytic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/multidrug-and-toxin-extrusion-transporter-1-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/multidrug-and-toxin-extrusion-transporter-2-k-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/muscle-relaxant 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/muscle-relaxant-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/muscle-relaxant-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/n-methyl-d-aspartate-receptor-antagonist 2026-01-03 weekly 0.8 https://prescriberpoint.com/class/n-substituted-glycines-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/neonatal-fc-receptor-blocker 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/neonatal-fc-receptor-blocker-%5Bepc%5D 2026-02-22 weekly 0.8 https://prescriberpoint.com/class/neonatal-fc-receptor-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/neonatal-fc-receptor-blockers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nerve-growth-factor-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/neuraminidase-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/neuraminidase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/neuraminidase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/neuroactive-steroid-gamma-aminobutyric-acid-a-receptor-positive-modulator 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/neuroactive-steroid-gamma-aminobutyric-acid-a-receptor-positive-modulator-%5Bepc%5D 2026-02-14 weekly 0.8 https://prescriberpoint.com/class/neuroactive-steroid-gamma-aminobutyric-acid-a-receptor-positive-modulator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/neurokinin-1-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/neurokinin-3-receptor-antagonist-%5Bepc%5D 2026-03-09 weekly 0.8 https://prescriberpoint.com/class/neurokinin-3-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/neurokinin-3-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/neuromuscular-blockade-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/neuromuscular-blocker 2026-01-02 weekly 0.8 https://prescriberpoint.com/class/neuromuscular-blocker-%5Bepc%5D 2026-03-08 weekly 0.8 https://prescriberpoint.com/class/neuromuscular-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nicotine-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nicotinic-acid 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/nicotinic-acid-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nicotinic-acids-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nitrate-vasodilator 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/nitrate-vasodilator-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/nitrate-vasodilator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nitrates-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nitrofuran-antibacterial 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/nitrofuran-antibacterial-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/nitrofuran-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nitrofurans-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nitroimidazole-antimicrobial 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/nitroimidazole-antimicrobial-%5Bepc%5D 2026-02-23 weekly 0.8 https://prescriberpoint.com/class/nitroimidazole-antimicrobial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nitroimidazoles-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/non-narcotic-antitussive 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/non-narcotic-antitussive-%5Bepc%5D 2026-04-16 weekly 0.8 https://prescriberpoint.com/class/non-narcotic-antitussive-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/non-nucleoside-reverse-transcriptase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/non-standardized-pollen-allergenic-extract-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/noncompetitive-ampa-glutamate-receptor-antagonist-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/noncompetitive-ampa-glutamate-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nondepolarizing-neuromuscular-blocker 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/nonergot-dopamine-agonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/nonergot-dopamine-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nonsteroidal-anti-inflammatory-drug 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/nonsteroidal-anti-inflammatory-drug-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/nonsteroidal-anti-inflammatory-drug-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nonsteroidal-mineralocorticoid-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/norepinephrine-releasing-agent 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/norepinephrine-reuptake-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/norepinephrine-uptake-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nuclear-export-inhibitor 2026-01-08 weekly 0.8 https://prescriberpoint.com/class/nuclear-export-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nuclear-export-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nucleic-acid-synthesis-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nucleoside-analog-antifungal-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nucleoside-analog-antiviral-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/nucleoside-analog-antiviral-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nucleoside-metabolic-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/nucleoside-metabolic-inhibitor-%5Bepc%5D 2026-02-08 weekly 0.8 https://prescriberpoint.com/class/nucleoside-metabolic-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nucleoside-reverse-transcriptase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/nucleosides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/oligonucleotide-telomerase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/oligonucleotides-antisense-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/opioid-agonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/opioid-agonist-%5Bepc%5D 2026-02-06 weekly 0.8 https://prescriberpoint.com/class/opioid-agonist-antagonist 2026-01-03 weekly 0.8 https://prescriberpoint.com/class/opioid-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/opioid-antagonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/opioid-antagonist-%5Bepc%5D 2026-02-26 weekly 0.8 https://prescriberpoint.com/class/opioid-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/opioid-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/opioid-mu-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/optical-imaging-agent 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/orexin-receptor-antagonist-%5Bepc%5D 2026-03-04 weekly 0.8 https://prescriberpoint.com/class/orexin-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/orexin-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/organic-anion-transporter-1-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/organic-anion-transporter-3-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/organic-anion-transporting-polypeptide-1b1-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/organic-anion-transporting-polypeptide-1b3-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/organic-anion-transporting-polypeptide-2b1-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/organic-cation-transporter-1-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/organic-cation-transporter-2-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/organometallic-compounds-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/orthopoxvirus-vp37-envelope-wrapping-protein-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/orthopoxvirus-vp37-envelope-wrapping-protein-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/osmotic-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/osmotic-diuretic-%5Bepc%5D 2026-04-24 weekly 0.8 https://prescriberpoint.com/class/osmotic-diuretic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/osmotic-laxative 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/osmotic-laxative-%5Bepc%5D 2026-04-23 weekly 0.8 https://prescriberpoint.com/class/osmotic-laxative-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/oxaborole-antifungal 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/oxaborole-antifungal-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/oxazolidinone-antibacterial-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/oxazolidinone-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/oxazolidinones-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/oxytocic 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/oxytocic-%5Bepc%5D 2026-02-16 weekly 0.8 https://prescriberpoint.com/class/oxytocic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/oxytocin-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/p-glycoprotein-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/p-glycoprotein-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/p-selectin-blockers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/p2y12-platelet-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/p2y12-platelet-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/p2y12-platelet-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/p2y12-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/paramagnetic-contrast-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/parathyroid-hormone-analog-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/parathyroid-hormone-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/parathyroid-hormone-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/parathyroid-hormone-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/parathyroid-hormone-related-peptide-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/parathyroid-hormone-related-protein-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/parenteral-iron-replacement-%5Bepc%5D 2026-03-06 weekly 0.8 https://prescriberpoint.com/class/parenteral-iron-replacement-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/partial-cholinergic-nicotinic-agonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/partial-opioid-agonist 2025-12-30 weekly 0.8 https://prescriberpoint.com/class/partial-opioid-agonist-%5Bepc%5D 2026-02-11 weekly 0.8 https://prescriberpoint.com/class/partial-opioid-agonist-antagonist 2026-01-19 weekly 0.8 https://prescriberpoint.com/class/partial-opioid-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/partial-opioid-agonistantagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/partial-opioid-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/passively-acquired-immunity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/pcsk9-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/pcsk9-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/pcsk9-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/pediculicide 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/pediculicide-%5Bepc%5D 2026-03-05 weekly 0.8 https://prescriberpoint.com/class/pediculicide-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/penem-antibacterial 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/penem-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/penicillin-class-antibacterial 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/peroxisome-proliferator-activated-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/peroxisome-proliferator-activated-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/peroxisome-proliferator-activated-receptor-alpha-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/peroxisome-proliferator-activated-receptor-gamma-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/peroxisome-proliferator-receptor-alpha-agonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/peroxisome-proliferator-receptor-alpha-agonist-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/peroxisome-proliferator-receptor-alpha-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/peroxisome-proliferator-receptor-gamma-agonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/peroxisome-proliferator-receptor-gamma-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/pharmacologic-cardiac-stress-test-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phenothiazine 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/phenothiazine-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phenothiazines-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phenylalanine-ammonia-lyase-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phenylalanine-hydroxylase-activator 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/phenylalanine-metabolizing-enzyme 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/phenylalanine-metabolizing-enzyme-%5Bepc%5D 2026-03-12 weekly 0.8 https://prescriberpoint.com/class/phenylalanine-metabolizing-enzyme-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phosphate-binder 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/phosphate-binder-%5Bepc%5D 2026-03-21 weekly 0.8 https://prescriberpoint.com/class/phosphate-binder-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phosphate-chelating-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phosphodiesterase-3-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/phosphodiesterase-3-inhibitor-%5Bepc%5D 2026-05-05 weekly 0.8 https://prescriberpoint.com/class/phosphodiesterase-3-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phosphodiesterase-3-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phosphodiesterase-4-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/phosphodiesterase-4-inhibitor-%5Bepc%5D 2026-02-05 weekly 0.8 https://prescriberpoint.com/class/phosphodiesterase-4-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phosphodiesterase-4-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phosphodiesterase-5-inhibitor 2026-01-02 weekly 0.8 https://prescriberpoint.com/class/phosphodiesterase-5-inhibitor-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/phosphodiesterase-5-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phosphodiesterase-5-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/phosphoinositide-3-kinase-alpha-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/photoabsorption-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/photoactivated-radical-generator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/photoenhancer 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/photoenhancer-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/photosensitizing-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/plasma-kallikrein-inhibitor 2026-01-10 weekly 0.8 https://prescriberpoint.com/class/plasma-kallikrein-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/plasma-volume-expander-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/platelet-aggregation-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/platelet-aggregation-inhibitor-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/platelet-aggregation-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/platelet-derived-growth-factor-alpha-receptor-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/platelet-derived-growth-factor-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/platinum-based-drug 2025-12-30 weekly 0.8 https://prescriberpoint.com/class/platinum-based-drug-%5Bepc%5D 2026-04-17 weekly 0.8 https://prescriberpoint.com/class/platinum-based-drug-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/pollen-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/poly(adp-ribose)-polymerase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/polyadp-ribose-polymerase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/polyadp-ribose-polymerase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/polyene-antifungal 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/polyene-antifungal-%5Bepc%5D 2026-02-19 weekly 0.8 https://prescriberpoint.com/class/polyene-antifungal-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/polyene-antimicrobial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/polyenes-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/polymyxin-class-antibacterial 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/porphyrin-precursor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/positron-emitting-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/potassium-binder-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/potassium-binder-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/potassium-channel-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/potassium-channel-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/potassium-ion-binding-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/potassium-ion-exchange-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/potassium-sparing-diuretic 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/potassium-sparing-diuretic-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/potassium-sparing-diuretic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ppar-alpha-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/progestational-hormone-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/progesterone 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/progesterone-%5Bepc%5D 2026-02-22 weekly 0.8 https://prescriberpoint.com/class/progesterone-agonist-antagonist 2026-01-10 weekly 0.8 https://prescriberpoint.com/class/progesterone-congeners-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/progesterone-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/progesterone-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/progestin 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/progestin-%5Bepc%5D 2026-02-05 weekly 0.8 https://prescriberpoint.com/class/progestin-antagonist-%5Bepc%5D 2026-02-27 weekly 0.8 https://prescriberpoint.com/class/progestin-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/progestin-containing-intrauterine-system 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/progestin-containing-intrauterine-system-%5Bepc%5D 2026-02-05 weekly 0.8 https://prescriberpoint.com/class/progestin-containing-intrauterine-system-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/progestin-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/programmed-death-ligand-1-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/programmed-death-ligand-1-blocker 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/programmed-death-ligand-1-blocker-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/programmed-death-ligand-1-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/programmed-death-ligand-1-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/programmed-death-receptor-1-blocking-antibody 2026-01-08 weekly 0.8 https://prescriberpoint.com/class/programmed-death-receptor-1-blocking-antibody-%5Bepc%5D 2026-02-05 weekly 0.8 https://prescriberpoint.com/class/programmed-death-receptor-1-blocking-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/programmed-death-receptor-1-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/prostacyclin-receptor-agonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/prostacyclin-receptor-agonist-%5Bepc%5D 2026-04-21 weekly 0.8 https://prescriberpoint.com/class/prostacyclin-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/prostacyclin-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/prostacycline-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/prostacycline-vasodilator 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/prostacycline-vasodilator-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/prostacycline-vasodilator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/prostaglandin-analog 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/prostaglandin-analog-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/prostaglandin-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/prostaglandin-e1-agonist-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/prostaglandin-e1-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/prostaglandin-e1-analog-%5Bepc%5D 2026-02-19 weekly 0.8 https://prescriberpoint.com/class/prostaglandin-e1-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/prostaglandin-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/prostaglandins-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/prostaglandins-e-synthetic-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/prostaglandins-i-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/protease-activator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/protease-activators-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/protease-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/protease-inhibitor-%5Bepc%5D 2026-04-21 weekly 0.8 https://prescriberpoint.com/class/protease-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/proteasome-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/proteasome-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/proteasome-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/proteasome-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/protein-kinase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/protein-synthesis-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/proto-oncogene-tyrosine-protein-kinase-ros1-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/proton-pump-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/proton-pump-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/proton-pump-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/proton-pump-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/provitamin-d2-compound 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/provitamin-d2-compound-%5Bepc%5D 2026-02-13 weekly 0.8 https://prescriberpoint.com/class/provitamin-d2-compound-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/psoralen-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/psoralens-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/purine-antimetabolite 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/purine-antimetabolite-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/purine-antimetabolite-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/purines-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/pyrethrins-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/pyrethroid-%5Bepc%5D 2026-03-08 weekly 0.8 https://prescriberpoint.com/class/pyrethroid-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/pyridone 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/pyridone-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/pyridones-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/pyrimidine-synthesis-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/pyrimidine-synthesis-inhibitor-%5Bepc%5D 2026-02-28 weekly 0.8 https://prescriberpoint.com/class/pyrimidine-synthesis-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/pyrophosphate-analog-dna-polymerase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/pyruvate-kinase-activator 2026-01-10 weekly 0.8 https://prescriberpoint.com/class/pyruvate-kinase-activator-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/pyruvate-kinase-activator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/pyruvate-kinase-activators-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/quinolone-antimicrobial 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/quinolone-antimicrobial-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/quinolone-antimicrobial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/quinolones-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/radioactive-diagnostic-agent-%5Bepc%5D 2026-02-08 weekly 0.8 https://prescriberpoint.com/class/radioactive-diagnostic-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/radioactive-tracers-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/radiographic-contrast-agent 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/radiographic-contrast-agent-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/radiographic-contrast-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/radioligand-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/radioligand-therapeutic-agent-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/radioligand-therapeutic-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/radiopharmaceutical-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/rank-ligand-blocking-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/rank-ligand-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/rank-ligand-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/rearranged-during-transfection-ret-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/receptor-tyrosine-kinase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/recombinant-fusion-proteins-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/recombinant-human-deoxyribonuclease-1 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/recombinant-human-deoxyribonuclease-1-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/recombinant-human-growth-hormone 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/recombinant-human-growth-hormone-%5Bepc%5D 2026-04-03 weekly 0.8 https://prescriberpoint.com/class/recombinant-human-growth-hormone-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/recombinant-human-nerve-growth-factor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/recombinant-proteins-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/reducing-and-complexing-thiol 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/reducing-and-complexing-thiol-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/reduction-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/renal-dehydropeptidase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/renal-dehydropeptidase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/respiratory-syncytial-virus-anti-f-protein-monoclonal-antibody 2026-01-15 weekly 0.8 https://prescriberpoint.com/class/respiratory-syncytial-virus-anti-f-protein-monoclonal-antibody-%5Bepc%5D 2026-04-23 weekly 0.8 https://prescriberpoint.com/class/respiratory-syncytial-virus-anti-f-protein-monoclonal-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/retinoid 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/retinoid-%5Bepc%5D 2026-02-05 weekly 0.8 https://prescriberpoint.com/class/retinoid-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/retinoids-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/reversed-anticoagulation-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/rifamycin-antibacterial 2026-01-07 weekly 0.8 https://prescriberpoint.com/class/rifamycin-antibacterial-%5Bepc%5D 2026-02-18 weekly 0.8 https://prescriberpoint.com/class/rifamycin-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/rifamycin-antimycobacterial 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/rifamycin-antimycobacterial-%5Bepc%5D 2026-02-11 weekly 0.8 https://prescriberpoint.com/class/rifamycin-antimycobacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/rifamycins-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/rna-replicase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/rna-small-interfering-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/rna-synthetase-inhibitor-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/rna-synthetase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/salivary-proteins-and-peptides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sars-cov-2-nucleotide-analog-rna-polymerase-inhibitor-%5Bepc%5D 2026-02-20 weekly 0.8 https://prescriberpoint.com/class/sars-cov-2-nucleotide-analog-rna-polymerase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sclerosing-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sclerosing-agent 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/sclerosing-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/selectin-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/selective-estrogen-receptor-modulators-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/selective-t-cell-costimulation-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/selective-t-cell-costimulation-modulator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/semifluorinated-alkane-%5Bepc%5D 2026-03-15 weekly 0.8 https://prescriberpoint.com/class/semifluorinated-alkane-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/serotonin-1b-and-serotonin-1d-receptor-agonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/serotonin-1b-and-serotonin-1d-receptor-agonist-%5Bepc%5D 2026-02-05 weekly 0.8 https://prescriberpoint.com/class/serotonin-1b-and-serotonin-1d-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/serotonin-1b-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/serotonin-1d-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/serotonin-3-receptor-antagonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/serotonin-3-receptor-antagonist-%5Bepc%5D 2026-03-12 weekly 0.8 https://prescriberpoint.com/class/serotonin-3-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/serotonin-3-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/serotonin-4-receptor-agonist-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/serotonin-4-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/serotonin-4-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/serotonin-and-norepinephrine-reuptake-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/serotonin-and-norepinephrine-reuptake-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/serotonin-reuptake-inhibitor 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/serotonin-reuptake-inhibitor-%5Bepc%5D 2026-02-07 weekly 0.8 https://prescriberpoint.com/class/serotonin-reuptake-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/serotonin-uptake-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sigma-1-agonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/skeletal-muscle-relaxant 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/skin-test-antigen-%5Bepc%5D 2026-04-22 weekly 0.8 https://prescriberpoint.com/class/skin-test-antigen-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/slamf7-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/slamf7-directed-immunostimulatory-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/small-interfering-rna-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/smoothened-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sodium-channel-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sodium-channel-blocker-%5Bepc%5D 2026-02-19 weekly 0.8 https://prescriberpoint.com/class/sodium-channel-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sodium-glucose-cotransporter-2-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/sodium-glucose-cotransporter-2-inhibitor-%5Bepc%5D 2026-02-05 weekly 0.8 https://prescriberpoint.com/class/sodium-glucose-cotransporter-2-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sodium-glucose-transporter-2-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/soluble-guanylate-cyclase-stimulator-%5Bepc%5D 2026-02-09 weekly 0.8 https://prescriberpoint.com/class/soluble-guanylate-cyclase-stimulator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/somatostatin-analog 2026-01-08 weekly 0.8 https://prescriberpoint.com/class/somatostatin-analog-%5Bepc%5D 2026-02-21 weekly 0.8 https://prescriberpoint.com/class/somatostatin-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/somatostatin-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sphingosine-1-phosphate-receptor-modulator 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/sphingosine-1-phosphate-receptor-modulator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sphingosine-1-phosphate-receptor-modulators-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/standardized-animal-hair-allergenic-extract-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/standardized-insect-allergenic-extract-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/standardized-pollen-allergenic-extract-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/starch-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/stem-cell-factor-kit-receptor-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sterol-esterase-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/stimulation-large-intestine-fluidelectrolyte-secretion-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/substance-p-neurokinin-1-receptor-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/substance-p-neurokinin-1-receptor-antagonist-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/substance-pneurokinin-1-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sucrose-specific-enzyme 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/sucrose-specific-enzyme-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sulfonamide-antibacterial 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/sulfonamide-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sulfonamide-antimicrobial-%5Bepc%5D 2026-03-01 weekly 0.8 https://prescriberpoint.com/class/sulfonamide-antimicrobial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sulfonamides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sulfone 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/sulfone-%5Bepc%5D 2026-03-05 weekly 0.8 https://prescriberpoint.com/class/sulfone-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sulfones-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sulfonylurea 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/sulfonylurea-%5Bepc%5D 2026-02-16 weekly 0.8 https://prescriberpoint.com/class/sulfonylurea-compounds-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sulfonylurea-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/surfactant 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/surfactant-%5Bepc%5D 2026-04-03 weekly 0.8 https://prescriberpoint.com/class/surfactant-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/surfactant-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/survival-motor-neuron-2-directed-rna-interaction-%5Bepc%5D 2026-04-08 weekly 0.8 https://prescriberpoint.com/class/survival-motor-neuron-2-directed-rna-interaction-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/survival-of-motor-neuron-2-splicing-modifier 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/survival-of-motor-neuron-2-splicing-modifier-%5Bepc%5D 2026-03-01 weekly 0.8 https://prescriberpoint.com/class/survival-of-motor-neuron-2-splicing-modifier-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/survival-of-motor-neuron-2-splicing-modifiers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/sympathomimetic-amine-anorectic 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/sympathomimetic-like-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/t-lymphocyte-costimulation-activity-blockade-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tetracycline-class-antibacterial-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tetracycline-class-antimicrobial 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/tetracycline-class-drug 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/tetracycline-class-drug-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/tetracycline-class-drug-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tetracyclines-chemicalingredient 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tetracyclines-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thalidomide-analog-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/thalidomide-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thiazide-diuretic 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/thiazide-diuretic-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/thiazide-diuretic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thiazide-like-diuretic 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/thiazide-like-diuretic-%5Bepc%5D 2026-02-05 weekly 0.8 https://prescriberpoint.com/class/thiazide-like-diuretic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thiazides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thiazolidinedione 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/thiazolidinedione-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thiazolidinediones-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thrombin-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thrombopoietin-receptor-agonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/thrombopoietin-receptor-agonist-%5Bepc%5D 2026-03-15 weekly 0.8 https://prescriberpoint.com/class/thrombopoietin-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thrombopoietin-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thymic-stromal-lymphopoietin-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thymic-stromal-lymphopoietin-blockers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thyroid-hormone-receptor-beta-agonist 2025-11-02 weekly 0.8 https://prescriberpoint.com/class/thyroid-hormone-receptor-beta-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thyroid-hormone-receptor-beta-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thyroid-hormone-synthesis-inhibitor-%5Bepc%5D 2026-03-15 weekly 0.8 https://prescriberpoint.com/class/thyroid-hormone-synthesis-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thyroid-hormone-synthesis-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thyroid-stimulating-hormone-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/thyrotropin-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tissue-factor-pathway-inhibitor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tissue-factor-pathway-inhibitor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tissue-nonspecific-alkaline-phosphatase 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/tissue-nonspecific-alkaline-phosphatase-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/topoisomerase-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/topoisomerase-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/topoisomerase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/topoisomerase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/transthyretin-directed-rna-interaction 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/transthyretin-directed-rna-interaction-%5Bepc%5D 2026-03-09 weekly 0.8 https://prescriberpoint.com/class/transthyretin-directed-rna-interaction-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tricyclic-antidepressant 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/tricyclic-antidepressant-%5Bepc%5D 2026-02-26 weekly 0.8 https://prescriberpoint.com/class/tricyclic-antidepressant-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/triglycerides-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tropomyosin-receptor-kinases-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tropomyosin-receptor-tyrosine-kinase-a-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tropomyosin-receptor-tyrosine-kinase-b-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tropomyosin-receptor-tyrosine-kinase-c-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/trpm8-thermoreceptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/trpm8-thermoreceptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tuberculosis-skin-test-%5Bepc%5D 2026-04-22 weekly 0.8 https://prescriberpoint.com/class/tuberculosis-skin-test-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tubulin-inhibiting-agent 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/tubulin-inhibiting-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tumor-necrosis-factor-blocker 2025-12-30 weekly 0.8 https://prescriberpoint.com/class/tumor-necrosis-factor-blocker-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/tumor-necrosis-factor-blocker-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tumor-necrosis-factor-receptor-blocking-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/type-i-interferon-receptor-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/type-i-interferon-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/type-i-interferon-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/type-ii-raf-kinase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/typical-antipsychotic 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/typical-antipsychotic-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/typical-antipsychotic-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tyrosine-kinase-2-inhibitor-%5Bepc%5D 2026-03-21 weekly 0.8 https://prescriberpoint.com/class/tyrosine-kinase-2-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tyrosine-kinase-2-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/tyrosine-kinase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/udp-glucuronosyltransferases-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ugt1a1-inducers-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ugt1a1-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ugt1a9-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ugt2b7-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/ultrasound-contrast-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/uncompetitive-n-methyl-d-aspartate-receptor-antagonist 2025-07-23 weekly 0.8 https://prescriberpoint.com/class/unfractionated-heparin-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/urate-oxidase-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/urea-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/urease-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/urease-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/uric-acid-specific-enzyme-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vaccines-attenuated-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vascular-endothelial-growth-factor-directed-antibody-interactions-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vascular-endothelial-growth-factor-inhibitor 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/vascular-endothelial-growth-factor-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/vascular-endothelial-growth-factor-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vascular-endothelial-growth-factor-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vascular-endothelial-growth-factor-receptor-2-antagonist 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/vascular-endothelial-growth-factor-receptor-2-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vascular-sclerosing-activity-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vasoconstriction-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vasoconstrictor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vasodilation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vasodilator 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/vasodilator-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/vasodilator-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vasopressin-analog 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/vasopressin-receptor-agonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vasopressin-receptor-agonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vasopressin-v2-receptor-antagonist-%5Bepc%5D 2026-04-09 weekly 0.8 https://prescriberpoint.com/class/vasopressin-v2-receptor-antagonist-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vasopressin-v2-receptor-antagonists-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vasopressins-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vegfr2-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/venous-vasodilation-pe 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vesicular-monoamine-transporter-2-inhibitor-%5Bepc%5D 2026-04-10 weekly 0.8 https://prescriberpoint.com/class/vesicular-monoamine-transporter-2-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vesicular-monoamine-transporter-2-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vinca-alkaloid 2026-01-03 weekly 0.8 https://prescriberpoint.com/class/virus-neutralization-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vitamin-b-12-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vitamin-b12 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/vitamin-b12-%5Bepc%5D 2026-03-15 weekly 0.8 https://prescriberpoint.com/class/vitamin-b12-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vitamin-b6-analog 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/vitamin-c 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/vitamin-c-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/vitamin-c-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vitamin-d 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/vitamin-d-%5Bepc%5D 2026-02-19 weekly 0.8 https://prescriberpoint.com/class/vitamin-d-analog 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/vitamin-d-analog-%5Bepc%5D 2026-05-08 weekly 0.8 https://prescriberpoint.com/class/vitamin-d-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vitamin-d-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vitamin-d-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vitamin-d2-analog 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/vitamin-d2-analog-%5Bepc%5D 2026-03-13 weekly 0.8 https://prescriberpoint.com/class/vitamin-d2-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vitamin-d3-analog 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/vitamin-d3-analog-%5Bepc%5D 2026-03-13 weekly 0.8 https://prescriberpoint.com/class/vitamin-d3-analog-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vitamin-k 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/vitamin-k-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/vitamin-k-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/vitamin-k-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/warfarin-reversal-agent 2026-01-09 weekly 0.8 https://prescriberpoint.com/class/warfarin-reversal-agent-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/warfarin-reversal-agent-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/x-ray-contrast-activity-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/xanthine-oxidase-inhibitor 2026-01-08 weekly 0.8 https://prescriberpoint.com/class/xanthine-oxidase-inhibitor-%5Bepc%5D 2026-02-04 weekly 0.8 https://prescriberpoint.com/class/xanthine-oxidase-inhibitor-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/xanthine-oxidase-inhibitors-moa 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/xanthines-cs 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/zaire-ebolavirus-glycoprotein-directed-antibody-%5Bepc%5D 2026-03-05 weekly 0.8 https://prescriberpoint.com/class/zaire-ebolavirus-glycoprotein-directed-antibody-epc 2026-06-13 weekly 0.8 https://prescriberpoint.com/class/zaire-ebolavirus-glycoprotein-directed-antibody-interactions-moa 2026-06-13 weekly 0.8